Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Lecture contents
3. Allergy and asthma
4. Action of omalizumab
5. Clinical trial for omalizumab
6. Results of clinical trial
7. Secondary outcomes
8. Omalizumab licence
9. Practical considerations
10. Expanded dose table
11. What do guidelines say about omalizumab?
12. Severe asthma
13. Current situation
14. SMC decision
15. NICE final appraisal determination (1)
16. RBH difficult asthma protocol
17. NICE final appraisal determination (2)
18. Monitoring
19. Evidence from Joint task force
20. Summary of recommendations
21. Summary of timing of adverse reactions
22. Monitoring after injections
23. NICE vs. SMC
24. Median daily OCS use
25. Median AQLQ total scores
26. Median FEV1
27. Current UK practice
28. A retrospective analysis of omalizumab treatment
29. Objectives
30. Eligibility
31. Patient demographics
32. OCS daily dose
33. Percentage stopping or reducing OCS use
34. Asthma exacerbations pre and post OMB
35. Quality of life pre and post OMB
36. NHS resource use - hospitalisations
37. NHS resource use - no. days hospitalised
38. Lung function pre and post OMB initiation
39. How long to treat?
40. Research evidence
41. FEV1 after omalizumab withdrawal
42. Asthma after stopping omalizumab
43. Asthma medication changed after omalizumab
44. Conclusions

Topics Covered

• Anti-IgE therapy for asthma
• Allergy can be associated with severe asthma
• Omalizumab, a monoclonal anti-IgE, is the first targeted biological therapy for severe asthma with good clinical efficacy
• Patient selection, drug administration and length of treatment are discussed

Links

Series:

• Advances in Asthma

Categories:

• Cell Biology
• Clinical Medicine
• Diseases, Disorders & Treatments
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Menzies-Gow, A. (2013, January 17). Anti-IgE therapy for asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2019, from https://hstalks.com/bs/2474/.

Publication History

• Published on January 17, 2013

Financial Disclosures

• Dr. Andrew Menzies-Gow has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.